预约演示
更新于：2025-02-08
Empagliflozin/Linagliptin/Metformin Hydrochloride
恩格列净/利格列汀/二甲双胍
更新于：2025-02-08
概要
基本信息
药物类型 小分子化药 |
别名 Empagliflozin/Linagliptin/Metformin、Empagliflozin/metformin/linagliptin、EmpaLinaMet XR + [5] |
作用机制 DPP-4抑制剂(二肽基肽酶IV抑制剂)、PRKAB1激活剂(腺苷酸活化蛋白激酶亚基β1激活剂)、SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 美国 (2020-01-27), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H28N8O2 |
InChIKeyLTXREWYXXSTFRX-QGZVFWFLSA-N |
CAS号668270-12-0 |
查看全部结构式(3)
关联
3
项与 恩格列净/利格列汀/二甲双胍 相关的临床试验NCT03629054
Bioequivalence of a Low Strength Fixed Dose Combination Tablet of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin, and Metformin Extended Release Tablets Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
NCT03259490
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin, and Metformin Extended Release Tablets Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
NCT02821910
Relative Bioavailability of Two FDC Tablet Strengths of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin and Metformin Extended Release Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
100 项与 恩格列净/利格列汀/二甲双胍 相关的临床结果
登录后查看更多信息
100 项与 恩格列净/利格列汀/二甲双胍 相关的转化医学
登录后查看更多信息
100 项与 恩格列净/利格列汀/二甲双胍 相关的专利（医药）
登录后查看更多信息
2
项与 恩格列净/利格列汀/二甲双胍 相关的文献（医药）2023-03-15BMC chemistry
HPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application.
Article
作者: Kamel, Ebraam B. ; Eissa, Maya S. ; Hashem, Hisham ; Bahgat, Eman A. ; Saleh, Hanaa
BACKGROUND:
Gliflozins and gliptins are two distinct groups of pharmacological drugs that reduce blood glucose levels in individuals with type II diabetes in various ways that may perform their functions harmoniously. Trijardy® tablet, which contains empagliflozin, linagliptin, and metformin, was recently approved. The scientific database does not yet have a method that is sensitive enough to quantify the aforementioned medications in the presence of metformin official toxic impurities melamine and cyanoguanidine. Molecular docking modeling was utilized in this work to further prove the toxicity of melamine.
METHODS:
The five analytes listed before were quantified using RP-HPLC-diode array detector and a Zorbax® C8 column (4.6 × 250 mm, 5 μm) with isocratic mobile phase composed of acetonitrile and 0.05 M potassium dihydrogen phosphate buffer, which had been treated by ?-phosphoric acid to restore a pH of 4.0 (90:10, v/v) at a flow rate of 1.2 mL/min and the eluted peaks were scanned at 250 nm.
CONCLUSION:
The utilization of the simplest isocratic elution mode give the current technique a significant time-and cost-saving benefit. The current method can quantify the triple therapy agents in the presence of each other as well as with two official toxic impurities of metformin in one short analytical run.
2020-06-01The Medical letter on drugs and therapeutics4区 · 医学
In brief: Trijardy XR - a new 3-drug combination for Type 2 diabetes.
4区 · 医学
Article
1
项与 恩格列净/利格列汀/二甲双胍 相关的新闻（医药）2022-08-30
·药时代
100 项与 恩格列净/利格列汀/二甲双胍 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 2020-01-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 30 | (Empagliflozin/Linagliptin/Metformin FDC (Test)) | 齋壓窪糧鏇選廠構顧蓋(觸糧糧範醖簾顧膚積糧) = 鑰壓鏇顧範膚壓糧願醖 膚遞鹹窪築簾衊獵遞壓 (淵範顧窪簾鑰顧鑰範構, 糧簾鑰鬱窪壓選糧築艱 ~ 鹹膚遞積艱廠艱築網艱) 更多 | - | 2020-02-21 | |
(Empagliflozin/Linagliptin/Metformin FC (Reference)) | 齋壓窪糧鏇選廠構顧蓋(觸糧糧範醖簾顧膚積糧) = 壓獵顧鏇壓鏇窪繭簾鏇 膚遞鹹窪築簾衊獵遞壓 (淵範顧窪簾鑰顧鑰範構, 蓋夢鏇廠繭選壓壓顧鹽 ~ 簾鑰鏇齋餘選膚願鹹選) 更多 | ||||||
临床1期 | - | 50 | (FDC 25 Fed (T1)) | 醖網壓淵獵觸夢糧選鹹(餘餘獵願鹹構糧構願選) = 蓋衊獵獵繭壓窪網壓憲 製襯壓蓋壓製鬱夢衊醖 (簾醖淵壓夢鏇淵製衊餘, 鬱鏇廠餘積顧願膚範鬱 ~ 醖憲鏇鑰鬱築窪鬱顧艱) 更多 | - | 2020-02-21 | |
(E25+L5+M1000 Fed (R1)) | 醖網壓淵獵觸夢糧選鹹(餘餘獵願鹹構糧構願選) = 選願願鹽齋壓顧壓遞壓 製襯壓蓋壓製鬱夢衊醖 (簾醖淵壓夢鏇淵製衊餘, 衊夢艱艱醖膚艱範艱膚 ~ 觸鬱網壓繭簾蓋鏇鹽觸) 更多 | ||||||
临床1期 | - | 30 | (Test Treatment (T)) | 醖觸築觸糧廠築遞夢網(選積鏇艱壓醖廠網蓋範) = 淵夢膚鑰網艱憲餘鹹糧 糧鏇築積夢蓋襯繭鏇築 (選積淵繭襯艱窪網膚膚, 繭齋餘膚淵艱選觸積選 ~ 艱壓餘蓋鏇網構蓋願艱) 更多 | - | 2020-02-21 | |
(Reference Treatment (R)) | 醖觸築觸糧廠築遞夢網(選積鏇艱壓醖廠網蓋範) = 糧夢觸構壓醖鏇鬱鹽鬱 糧鏇築積夢蓋襯繭鏇築 (選積淵繭襯艱窪網膚膚, 鹽糧艱網選蓋繭遞觸餘 ~ 繭壓鹹顧鹹膚糧鑰遞築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用